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S U M M A R Y
Vibrio vulniﬁcus is a halophilic Gram-negative bacillus found worldwide in warm coastal waters. The
pathogen has the ability to cause primary sepsis in certain high-risk populations, including patients with
chronic liver disease, immunodeﬁciency, iron storage disorders, end-stage renal disease, and diabetes
mellitus. Most reported cases of primary sepsis in the USA are associated with the ingestion of raw or
undercooked oysters harvested from the Gulf Coast. The mortality rate for patients with severe sepsis is
high, exceeding 50% in most reported series. Other clinical presentations include wound infection and
gastroenteritis. Mild to moderate wound infection and gastroenteritis may occur in patients without
obvious risk factors. Severe wound infection is often characterized by necrotizing skin and soft-tissue
infection, including fasciitis and gangrene. V. vulniﬁcus possesses several virulence factors, including the
ability to evade destruction by stomach acid, capsular polysaccharide, lipopolysaccharide, cytotoxins,
pili, and ﬂagellum. The preferred antimicrobial therapy is doxycycline in combination with ceftazidime
and surgery for necrotizing soft-tissue infection.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Vibrio vulniﬁcus is a halophilic, motile, Gram-negative bacillus
capable of causing severe to life-threatening infection in suscepti-
ble individuals. The spectrum of illness can vary from gastroen-
teritis to ‘primary sepsis’ and necrotizing fasciitis. The case-fatality
rate has been reported to exceed 50% in primary sepsis. Infection
may result from consuming or handling contaminated seafood
(usually shellﬁsh such as oysters) or from exposing open wounds
or broken skin to contaminated salt or brackish water.1–5
V. vulniﬁcus is usually found worldwide in coastal or estuarine
environments with water temperatures from 9 to 31 8C. The
organisms preferred habitat, however, is considerably more
selective and has been reported to be water temperatures in
excess of 18 8C and salinities between 15 to 25 parts per thousand
(ppt).6–8 However, salinities at or greater than 30 ppt will
substantially reduce the burden of V. vulniﬁcus regardless of the* Corresponding author. Tel.: +1 361 902 4906; fax: +1 361 882 8786.
E-mail address: mike.horseman@christushealth.org (M.A. Horseman).
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doi:10.1016/j.ijid.2010.11.003water temperature.8 As a result, most cases of infection can be
traced to tropical or subtropical sources. Even so, small outbreaks
related to local seawater or seafood exposure have occurred in
temperate climates as far north as Denmark during the summer
months.6 A recent report from Israel described several cases of
soft-tissue infection resulting from the handling and processing of
ﬁsh (tilapia or carp) raised in freshwater aquaculture ponds.9
Three biotypes of V. vulniﬁcus are known to cause severe
human disease. Biotype 1 is found worldwide in salt or brackish
water. Biotype 2 occupies a more speciﬁc niche and is found in
saltwater used for eel (genus Anguilla) farming in the Far East and
Western Europe.6,7 Biotype 3 is the strain associated with
freshwater ﬁsh farming in Israel. Genomic analyses of biotype 3
indicate it is a hybrid of biotypes 1 and 2.9 Biotype 1 is the most
common strain and is responsible for the entire spectrum of
illness, including the primary sepsis associated with the often-
quoted fatality rate in excess of 50%. Biotype 2 is usually a serious
pathogen of eels, but on rare occasions may cause wound
infections in humans.3,6,7 Although biotype 3 can cause severe
soft-tissue infections requiring amputation, the mortality rate
appears to be less than 8%.9ses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Right arm about 24 h after admission.
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Figure 2. Left arm about 24 h after admission.
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in patients with chronic liver disease, immunodeﬁciencies, or
hematological disorders characterized by elevated iron levels.1–7,9–
12 Contamination with V. vulniﬁcus can be difﬁcult to detect
because the organism has no effect on the appearance, taste, or
odor of seafood, particularly raw oysters.13 Because V. vulniﬁcus is
ubiquitous in warm marine environments, water quality also has
little impact on the risk of infection.12
In this report, we describe a severe case of soft-tissue infection
and review much of the current literature concerning V. vulniﬁcus.
We also provide recommendations for treatment and prevention in
populations at high risk of infection.
2. Illustrative case
A 53-year-oldmalewas admitted to the emergency department
(ED) with a 2-day history of pain in both arms, which he
characterized as 10/10. The patient also complained of subjective
chills and fever. Vital signs on admission included a temperature of
37.2 8C, heart rate of 73/min, respiratory rate of 20/min, blood
pressure of 75/51 mmHg, and an oxygen saturation of 100% on
room air. The patient was noted to be grimacing but alert, and
oriented times 3 and cooperative. The left arm was erythematous
with petechiae to themedial aspect of the lower arm. The right arm
was erythematous to the anterior forearm with serosanginous
bullae.
Pertinent laboratory data included a white blood cell count
(WBC) of 8.6  109/l with 54% segmented neutrophils, 27% band
neutrophils, 8% lymphocytes, 11% monocytes; hemoglobin of
11.5 g/dl (7.1 mmol/l), hematocrit of 34.1%, platelet count of
30  109/l; prothrombin time (PT) of 15.7 s; activated partial
thrombin time (aPTT) of 35.1 s; international normalized ratio
(INR) of 1.6; ﬁbrinogen of 831 mg/dl (24.4mmol/l), D-dimer of
6.3 mg/l FEU (ﬁbrinogen equivalent units); serum creatinine of
5.8 mg/dl (512.7 mmol/l); blood urea nitrogen (BUN) of 52 mg/dl
(18.6mmol/l), sodiumof 121meq/l (121mmol/l); potassiumof 5.8
meq/l (5.8mmol/l); bicarbonate (HCO3
) of 11 mmol/l; glucose of
84 mg/dl (4.7 mmol/l); total bilirubin of 1.3 mg/dl (22.2mmol/l);
albumin of 2.6 g/dl; alkaline phosphatase of 203 U/l; acetamino-
phen of 47.6mg/ml (315.1 mmol/l); pH of 7.25; pCO2 of 21 mmHg;
and a B-type natriuretic peptide (BNP) of 1007 pg/ml. Blood and
blister ﬂuid cultures were collected and sent to the laboratory for
Gram stain, culture, and susceptibility testing.
Upon questioning, the patient provided no history of exposure
to saltwater. He was placed on vancomycin 1 g every 12 h. Past
medical history included hepatitis C (presumably from multiple
transfusions), chronic renal insufﬁciency, cirrhosis, hypertension,
congestive heart failure, and ethanol abuse (stopped 2.5 years prior
to admission). The patient’s toxicology screen was negative. While
in the ED, he was given a bolus followed by amaintenance infusion
of normal saline. The patient was also placed on a norepinephrine
infusion and titrated to maintain a systolic blood pressure >90
mmHg.
Hewas transferred to the intensive care unit (ICU). Vancomycin
was discontinued the next day following a nephrology consult and
was replaced with clindamycin 900 mg every 8 h. Ertapenem
500 mg every 24 h was also added to the patient’s antimicrobial
regimen. Hemorrhagic bullae appeared within the ﬁrst 24 h and
the affected integument extended from both hands to the elbows,
with the right hand (Figure 1) more involved than the left
(Figure 2). Eventually much of the area encompassing both
forearms became necrotic. The presumptive diagnosis was
necrotizing fasciitis. Blood cultures were negative; however blister
ﬂuid cultures were positive at 48 h for V. vulniﬁcus. The bacterium
was susceptible at 72 h to ampicillin, ampicillin–sulbactam,
aztreonam, cefazolin, ciproﬂoxacin, gentamicin, imipenem, piper-acillin–tazobactam, and trimethoprim–sulfamethoxazole. When
questioned about the laboratory ﬁnding, the patient admitted to
shucking and eating at least 8 raw oysters a few days prior to
admission. The antimicrobial regimen was changed to doxycycline
100 mg intravenous (IV) every 12 h and ceftazidime 1 g every 24 h
(adjusted to renal function).
The patient’s hypotension, metabolic acidosis, and thrombocy-
topenia responded to treatment and norepinephrine was discon-
tinued by 48 h after admission. Hemodialysis was also initiated. A
plastic surgery consult was requested when the patient stabilized,
and debridement was performed on hospital days 6 and 15. The
operative report indicated the infectionwas limited to the skin and
subcutaneous fat and did not involve the fascia. The ﬁnal diagnosis
was therefore changed to necrotizing cellulitis. Skin grafts were
performed on hospital days 36 and 39. The patient continued to
improve, although he remained on hemodialysis post-discharge.
He was discharged in stable condition on hospital day 40.
3. Epidemiology
V. vulniﬁcus is found on all coastlines of the USA where water
temperatures are sufﬁciently warm to support growth. It is one of
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documented to cause human disease. Other important pathogenic
species include Vibrio parahaemolyticus, Vibrio alginolyticus, Vibrio
ﬂuvialis, Photobacterium (Vibrio) damsela, nontoxigenic Vibrio
cholerae, and the rare toxigenic (cholera toxin-producing) ser-
ogroup (01) of V. cholerae.2,14–16 In 2007, the last complete year of
data, 95 cases of V. vulniﬁcus infection were reported to the US
Centers for Disease Control and Prevention (CDC). The outcome
was known for 83 of these 95 cases; 30 patients (36%) died. This
corresponds to 83% of all Vibrio-related deaths. The 95 cases
accounted for 107 isolates. Most isolates were obtained from blood
(64%) and wound (29%) cultures. V. vulniﬁcus was the most
common (34%) cause of Vibrio-related illness in the Gulf Coast
states (Texas, Louisiana, Mississippi, Alabama, and Florida), but
accounted for only 17% of cases nationwide. Most cases of V.
vulniﬁcus-related illness reported to the CDC since reporting
became mandatory have either occurred along the Gulf Coast or
can be traced to a Gulf Coast origin. The latter would include
contaminated seafood sold in other regions of the USA. Most cases
have occurred in the warm months from April to October.15
The spectrum of illness caused by V. vulniﬁcus essentially
manifests in three syndromes: gastroenteritis, ‘severe sepsis’, and
skin and soft-tissue infection. As mentioned previously, ‘sepsis or
severe sepsis’ appears to have theworst outcome (>50%mortality)
and may be the most common presentation of infection.
Gastroenteritis and primary septicemia usually result from theTable 1
Percentage (%) of patients with risk factors by clinical syndrome and epidemiologic stu
Study, year [Ref.]
Risk factors Blake et al.,
1979 [11]
Tacket et al.,
1984 [5]
Klo
198
Gastrointestinal n=
Liver disease
Alcoholism
Diabetes mellitus 14
Gastrointestinal
disease/surgerya
28
Heart disease
Hematological disorder
Immunodeﬁciencyb
Malignancy
Renal disease 14
Any chronic disease 28
Primary septicemia n=24 n=18 n=
Liver disease 75 66
Alcoholism
Diabetes mellitus
Gastrointestinal
disease/surgerya
Heart disease
Hematological disorder
Immunodeﬁciencyb
Malignancy
Renal disease
Any chronic disease 96 89
Wound infection n=15 n=9 n=
Liver disease 0 12
Alcoholism
Diabetes mellitus
Gastrointestinal
disease/surgerya
Heart disease
Hematological disorder
Immunodeﬁciencyb
Malignancy
Renal disease
Any chronic disease 33 56
a Includes gastritis, pancreatitis, regional enteritis, peptic ulcer disease, ischemic bow
b Includes HIV; patients receiving chemotherapy or immunosuppressive drugs (inc
arthritis, SLE, or other autoimmune disorders; and leukopenia or neutropenia.
c Includes 12 total patients listed in Tacket et al. data, Ref. 5.consumption of contaminated seafood, especially raw oysters. Skin
and soft-tissue infection typically results from handling contami-
nated seafood or from exposure of open wounds to water in which
the organism thrives. As mentioned previously, reports from Israel
indicate freshwater ﬁsh may harbor the organism. However, in the
USA, all reported cases have been traced to an organism acquired
from a marine environment or brackish inland lakes. Biotype 1 is
by far the predominant cause of human infection and presumably
the likely etiology of all reported cases in the USA.6,7,16
The prominent risk factor for V. vulniﬁcus infection is chronic
liver disease, especially cirrhosis due to alcoholism or chronic
hepatitides such as hepatitis B or C.1–7,9–12,16,17 Alcohol consump-
tion of as little as 30 ml/day was shown to increase the risk of
infection in one study.17 Other risk factors include immunodeﬁ-
ciencies involvingmacrophage and neutrophil dysfunction, such as
those due to underlying cancers or immunosuppressive chemo-
therapy (e.g., for cancer and arthritis), acquired immunodeﬁciency
syndrome, end-stage renal disease (especially patients receiving
parenteral iron), gastrointestinal disorders (e.g., surgery, ulcers,
achlorhydria), diabetes mellitus, and hematological disorders
characterized by elevated iron levels such as hemochromato-
sis1–7,10–12,16,18 (Table 1). Other potential contributing factors
include chronic disease, especially heart disease, and advanced age
(>60 years). As noted later in this discussion, the vastmajority of V.
vulniﬁcus-related illness has occurred in males. The bacterium
grows rapidly when transferrin saturation exceeds 70%.16,19dy
ntz et al.,
8 [1] c
Paik et al.,
1995 [70]
Shapiro et al.,
1998 [4]
Dechet et al.,
2008 [2]
7 n=23
14
14
5
11
10
0
5
16
5
35
38 n=92 n=181
79 80
73 65
4 35
18
26
18
10
17
7
97
17 n=189 n=428
22 20
32 22
20 23
10 7
34 34
8 6
9 7
10 12
7 16
68 74
el disease.
luding chronic corticosteroid use) for cancer, organ transplantation, rheumatoid
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which may partially explain the pathophysiologic mechanism
associated with V. vulniﬁcus and this disorder.12 It has been
estimated that susceptible individuals correspond to between 7%
and 16% of the adult population in the USA.12 ‘Healthy patients’,
i.e., patients with no identiﬁable risk factors for V. vulniﬁcus
infection, are believed to account for < 5% of all reported US cases
of primary sepsis.12 Individuals with chronic liver disease or
various immunodeﬁciencies have been reported to be up 80 times
more likely to develop primary sepsis than healthy individuals.20
The various estimates of the population at risk assume all
susceptible individuals are truly at risk. However, fairly recent data
suggest that chronic liver disease or even cirrhosis is not an
absolute risk factor for V. vulniﬁcus infection. This observation is
supported in part by the apparent low attack rate in individuals
with liver disease, the largest high-risk group. It has been
estimated that less than one case of V. vulniﬁcus-related illness
occurs in 10 000 meals of raw oysters served to individuals with
liver disease.12 It is also quite possible that only a subset of this
group constitutes the true high-risk population. The other
possibility is that not all environmental strains are equally
virulent. Additional evidence supporting an unequal risk within
the liver disease population comes from a pilot study designed to
establish biomarkers for determining individuals at risk for V.
vulniﬁcus infection.21,22 In the study, the investigators exposed
peripheral bloodmononuclear cells (PBMCs) collected fromdonors
with liver disease to the bacterium. The authors reported that
levels of proinﬂammatory cytokines elicited by the PBMCs in
response to V. vulniﬁcus had no association with serum levels of
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
or the AST/ALT ratio obtained at baseline from the PBMC donors.
However, PBMC glutathione levels, a measure of cellular oxidative
stress, correlated directly and highly signiﬁcantly with the release
of proinﬂammatory cytokines. PBMC glutathione is inversely
proportional to the oxidative stress. Oxidative stress is a common
denominator for many of the high-risk populations. The authors
concluded that individuals with biomarkers for oxidative stress
have an increased susceptibility to V. vulniﬁcus sepsis.21
4. Pathophysiology
V. vulniﬁcus possesses multiple virulence determinants.3,22 The
organism has the ability to evade destruction in highly acidic
environments such as the stomach. It is believed that this is
accomplished by two different mechanisms.3 In the presence of
lowpH and secondary oxidative stress, V. vulniﬁcus can up-regulate
production of lysine decarboxylase and manganese superoxide
dismutase (MnSOD).23–25 Lysine decarboxylase converts lysine to
cadaverine, which functions as both an acid neutralizer (through
deamination) and a superoxide radical scavenger.3,24 The other
inducible enzyme, MnSOD, also contributes to acid neutralization
and reduction of oxidative stress, however, the exact mechanism
involved in acid neutralization has not been elucidated.24,25
Current evidence suggests superoxide generation rather than acid
stress may be the initial triggering event for expression of both
enzymes.3 This observation is based on a study reporting poor
survival of V. vulniﬁcus when exposed to low pH under laboratory
conditions.26 However, another study reported dramatically
improved survival if the organism was exposed to slightly acid
pH prior to low pH.27 This observation would support the
argument that oxidative stress or possibly even other stress
responses must be active to provide the bacterium protection from
low pH.3
Once V. vulniﬁcus evades the upper gastrointestinal tract
defenses, it can penetrate the intestinal wall and enter the
bloodstream. One of the ﬁrst innate immune mechanisms theorganism encounters is complement. Complement activation and
opsonization are necessary for phagocytosis of V. vulniﬁcus by
polymorphonuclear leukocytes.3,28 As described later in more
detail, the exact role, or perhaps more precisely the relative
contribution, of polymorphonuclear leukocytes or neutrophils in
eliminating the bacterium is not known. However, current
evidence indicates neutrophils like macrophages secrete cytokines
that recruit additional leukocytes to the site of infection following
complement-mediated phagocytosis.29 Several of these cytokines
are believed to mediate the systemic inﬂammatory response
syndrome so often seen with V. vulniﬁcus-associated disease.
Among the proinﬂammatory cytokines speciﬁcally induced and
expressed in patients infected with the bacterium are interleukin
(IL)-1b, IL-6, IL-8, and tumor necrosis factor alpha (TNF-a).21,29,30
Although these mediators are likely promoters of the sepsis
syndrome, deﬁciencies of proinﬂammatory cytokines such as those
found in some patients with V. vulniﬁcus infection and chronic liver
disease are paradoxically associated with poor outcomes.21 This
would suggest that either extreme, i.e., inadequate cytokine
expression or overactive cytokine induction, may be or is a major
contributing factor to the high mortality associated with the
organism. Cytokine release in response to the bacterium may be
facilitated in part by the interaction of ‘pathogen-associated
molecular patterns’ with toll-like receptors found on intestinal
epithelial cells and macrophages.31–33 A surface lipoprotein and
ﬂagellin, a subunit of the ﬂagellum, have been identiﬁed as the
‘pathogen-associated molecular patterns’ associated with V.
vulniﬁcus.32
An in vitro study demonstrated that survival of V. vulniﬁcus in
human blood is inversely correlated with neutrophil phagocyto-
sis.34 The blood of patients with chronic liver disease appears to
have decreased neutrophil activity in comparison to blood of
normal volunteers. The response of neutrophils has been
implicated as a disease determinant for V. vulniﬁcus.34 The
organism has shown the ability to reduce the number of
lymphocytes and macrophages through apoptotic activity.31,35,36
However, it does not appear to have an impact on the quantity or
the activity of neutrophils.31,36
Surface expression of capsular polysaccharide (CPS) is another
virulence factor V. vulniﬁcus uses to survive the immune response.
This is accomplished in at least three different ways. CPS provides
resistance to opsonization by complement and subsequent
phagocytosis by macrophages, it confers resistance to the
bactericidal effects of serum, and ﬁnally, encapsulation masks
immunogenic structures that would normally activate nonspeciﬁc
host responses.3,22
As mentioned previously, hematological disorders character-
ized by elevated iron levels are a risk factor for V. vulniﬁcus
infection. The exact relationship between serum iron and virulence
for the bacterium remains unclear. However, serum iron levels
have been shown to correlate directly with the infectious dose of V.
vulniﬁcus injected into laboratory mice.37 Iron is believed to
facilitate V. vulniﬁcus infection by enhancing growth of the
organism and possibly by reducing the activity of neutrophils.38
V. vulniﬁcus has been shown to produce at least two siderophores:
vulnibactin (a catechol) and an unnamed hydroxamate side-
rophore. Vulnibactin is the primary siderophore for acquiring iron
from media and for scavenging iron from transferrin and holo-
transferrin.3,22 Deferoxamine, a hydroxamate siderophore derived
from Streptomyces pilosus, has clinical utility as a chelating agent in
acute iron intoxication and chronic iron overload disorders. It has
been shown to promote iron uptake and growth of V. vulniﬁcus and
other ferrophilic organisms in vitro.39 Deferoxamine has been
reported to be a risk factor for Yersinia enterocolitica sepsis and
mucormycosis (Rhizopus sp, Cunninghamella) when used as a
therapeutic agent for chronic iron or aluminum overload disorders
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sis).39–43 The signiﬁcance of the threat posed by the drug in
patients with excess iron is not known because Y. enterocolitica
sepsis and mucormycosis may occur in this population with or
without the use of deferoxamine. Nevertheless, it would seem
reasonable to conclude the drug adds some degree of risk for V.
vulniﬁcus infection independent of the patients iron stores.42,43
Other iron chelators such as deferiprone and deferasirox appear to
inhibit growth of V. vulniﬁcus in vitro and may even possess
antibacterial properties.42,44 In addition to siderophore-mediated
uptake, the bacterium has the ability to trap unbound iron through
a heme receptor (HupA).3,22,45
In addition to the mechanisms described above, V. vulniﬁcus
elaborates an exotoxin – hemolysin (VvhA) – a protein that
facilitates the release of iron fromhemoglobin.VvhAmaycontribute
to the bacterium’s virulence not only throughhemolytic activity but
also through other cytotoxic effects.22 Intradermal injection of
puriﬁed toxin into mice resulted in acute cellulitis with extensive
extracellular edema, damaged or necrotic fat cells, capillary
endothelial cells, and muscle cells, and mild inﬂammatory inﬁltra-
tion.46 On amoremicroscopic level, other studies of affected tissues
have demonstrated increased vascular permeability, apoptosis of
endothelial cells, induction of inducible nitric oxide synthase
activity, increased nitric oxide production, and possibly increased
neutrophil recruitment.3,22 The toxin causes cell death by pore
formation in the cellular membrane.47 Despite all the potentially
deleterious effects, the relative contribution of hemolysin to V.
vulniﬁcus-associated disease is not known. There is also data
suggesting the toxin may play a minor or even insigniﬁcant role in
the infectious process. This observation is based on an in vivo study
in mice using a wild strain and a mutant strain without the gene
(vvhA) for hemolysin production. When both were injected
intraperitoneally into iron-loadedmice, themutant strain produced
overall tissue damage and necrosis comparable to the wild strain.48
There was also no difference inmedian lethal dose (LD50). However,
in another study using a hemolysin-deﬁcient mutant, there was a
small difference in mortality favoring the wild type when both
strains were force-fed to mice. Histological examination of the
stomach and intestinalmucosa revealed severe necrotizing enteritis
in the mice fed the wild strain.49 These results would suggest that
VvhAmaynotbe responsible for the lethality ofV. vulniﬁcusandmay
be only a relative contributor to the tissue damage seen with the
organism. The most likely role of hemolysin in the disease process
would be facilitating bloodstream invasion following oral ingestion
of V. vulniﬁcus.49 Another possible explanation for the contradictory
body of evidence may be that the toxin is not usually expressed in
vivo; however other studies have not shown this to be the
case.22,46,50 Thus, hemolysinmay play a greater role in environmen-
tal survival than human infection.3
Another toxin previously believed to contribute to the
bacterium’s virulence is VvpE, an extracellular metalloprotease.
Puriﬁed VvpE has been shown to cause tissue necrosis, increased
vascular permeability leading to edema, and bullous lesions, all
characteristic of systemic disease caused by V. vulniﬁcus.3,22 The
increased vascular permeability caused by the enzyme is
associated with the generation of bradykinin.22,51 Bradykinin, a
vasodilator, appears to be essential for dissemination of the
organism.22,52 Other effects of VvpE include degradation of type IV
collagen and activation of procaspase 3. The former is a structural
component of basement membranes and the latter is involved in
cellular apoptosis.3,51 Despite all these deleterious effects, like
hemolysin, there appears to be controversy concerning the
enzyme’s contribution to V. vulniﬁcus-associated disease. Studies
of experimental infection using mutant strains deﬁcient in VvpE
showed no difference in LD50 in comparison to the parent strain in
local and systemic infections.3,22,49As mentioned previously, mutant V. vulniﬁcus strains unable to
produce either hemolysin or VvpE were similar in cytotoxicity to
the wild strains. To further help deﬁne the role of these toxins, a
double mutant was created, one without VvpE (vvpE) and
hemolysin (vvhA) genes.3,49,53,54 In mice, HEp-2 cells, and HeLa
cells, this strainwas also found to be highly cytotoxic.49 Thiswould
suggest another toxin is primarily responsible for the severe
disease seen with V. vulniﬁcus. Currently, the strongest evidence
supports RtxA1 (VvRtxA) as that other toxin.3,54,55 RtxA1 is a
member of the RTX family of toxins and is 80% to 90% homologous
with RtxA, an accessory toxin found in V. cholerae.53,54 At this time,
RtxA1 appears to be the key determinant responsible for the
characteristic cytotoxicity seen with V. vulniﬁcus.3,54,55 The toxin is
believed to trigger excessive production of reactive oxygen species
(ROS) by the host, leading to necrotic cell death and apoptosis.55 To
further deﬁne the role of RtxA1,mutant strains deﬁcient only in the
toxin were found to be clearly less cytotoxic than the wild strain.53
Studies of various mutants exposed to HeLa cells have
reinforced our knowledge of the contribution of the previously
described toxins to V. vulniﬁcus infection. Mutants without all
three toxins (RtxA1, VvpE, hemolysin) and doublemutantswithout
RtxA1 and hemolysin were found to be totally devoid of
cytotoxicity.3,53
Lipopolysaccharide (LPS), a known pyrogen, is believed to
mediate the endotoxic shock associatedwith severe disease. Direct
intraperitoneal (i.p.) injection of LPS endotoxin from V. vulniﬁcus
into laboratory rodents resulted in dramatic decreases in mean
arterial pressure and rapid death of the animals.3,30 The effect of
lipopolysaccharide on blood pressure appears to be mediated
through nitric oxide synthetase activity.3 Interestingly, low-
density lipoprotein (LDL) cholesterol and estrogen may be
protective against LPS. In the animal model, mice pretreated with
LDL cholesterol demonstrated lower or delayed mortality follow-
ing exposure to LPS than controls.3 The evidence for estrogen is
observational. Males disproportionately outnumber females in
terms of cases of V. vulniﬁcus-related infection.56
Other virulence factors affect attachment and motility. Cell to
cell contact with adherence and production of pili is essential for
the cytotoxic effects of V. vulniﬁcus.3,22,53 Mutants with the
inability to encode for either the pili structural protein (gene
pilA) or prepilin peptidase (gene pilD) demonstrated a loss of
attachment and slight increases in LD50 in comparison to the
parent strain.7,57 Furthermore loss of pilD resulted in an overall
reduction of cytotoxicity.3,22,57 Two other membrane proteins,
OmpU and IlpA, are also believed to contribute to the virulence of
V. vulniﬁcus. OmpU is an outer membrane protein capable of
binding ﬁbronectin, while IlpA, a surface lipoprotein, appears to be
an immunostimulant.33,58 Studies of mutants devoid of either
protein and injected i.p. intomice showed reduced cytotoxicity but
only a sight increase in LD50 in comparison to the wild strain.
33,58
This would suggest both proteins contribute primarily to local
tissue effects but are not essential for lethality.3 In V. vulniﬁcus, the
ﬂagellum is not only an organelle responsible for motility but also
appears to enhance pathogenesis. Loss of motility may lead to
decreased adhesion to the host cells and an inhibition of cytotoxin
delivery.3,59
5. Clinical presentation
Asmentioned previously, V. vulniﬁcus-related infections usually
manifest as one of three clinical syndromes: gastroenteritis,
primary sepsis, and wound infection. Rare cases of spontaneous
bacterial peritonitis,60 pneumonia,61 endometritis,62 meningitis,63
septic arthritis,64 osteomyelitis,65 endophthalmitis,66,67 and kera-
titis67 have also been reported and should be considered atypical
presentations. Gastroenteritis is characterized by complaints (in
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nausea, vomiting, diarrhea, fever, and chills.1,4 The bullous skin
lesions observed with other forms of V. vulniﬁcus-related disease
do not occur with gastroenteritis. Gastrointestinal symptoms are
typically described as mild to moderate or even self-limited and
may occur in individuals without the previously identiﬁed risk
factors for the organism.1,4 Death is rare, but has been reported in
one series as high as 9%. It is likely that most if not all fatalities
associated with V. vulniﬁcus gastroenteritis resulted from undiag-
nosed sepsis.4
Severe sepsis in some series has been described as the most
common presentation of V. vulniﬁcus-associated disease or at the
very least, a close second to wound infection.1,4,5,11 Primary sepsis
is usually characterized by bacteremia without an obvious focus of
infection. Positive tissue culture (bullous lesion or exudate
collected during debridement) without evidence of open wounds
on presentation would also be included in this category. The portal
of entry is believed to be the small intestine or the proximal colon
(cecum) with the ileum as the most likely site.68 Symptoms
typically occur within 7 days, although they may be delayed up to
14 days in cases of the ingestion of raw or undercooked seafood.69
Themost common source of infection in the USA is consumption of
raw oysters from the Gulf Coast.4 All Gulf Coast oysters are
reported to harbor V. vulniﬁcus during the summer months.
Primary sepsis typically presents with an abrupt onset of fever and
chills. Metastatic infection characterized by cutaneous lesions such
as bullae, cellulitis, ecchymosis, or even ‘generalized macular or
maculopapular eruptions’ are common and usually occur on the
lower extremities or the trunk. Gastrointestinal complaints such as
nausea, vomiting, and abdominal pain often precede fever, chills,
and cutaneous manifestations. Cutaneous lesions may progress to
necrotic ulcers, necrotizing fasciitis, necrotizing vasculitis, or
myonecrosis.1,4,5,11,69,70 Septic shock (systolic blood pressure <90
mmHg) was reported in almost two-thirds of patients in one
series.4 Hypotension during the ﬁrst 12 h or leukopenia is often
associated with a very poor prognosis.1 Another series reported
mental status changes characterized by obtundation, lethargy, or
disorientation in half the patients.1,4 Thrombocytopenia is also
very common and in an early study by the CDC, the frequency of
disseminated intravascular coagulation (DIC) was only slightly less
than the previouslymentionedmortality rate of 50%.11 At least one
report has described a case complicated by purpura fulminans.71
Wound infection often differs from primary sepsis only in the
presence of a cutaneous portal of entry. Infection may result from
entry of V. vulniﬁcus into pre-existing wounds or from inoculation
of traumatic injuries. Pre-existingwoundsmay become infected by
simply swimming or wading in environments containing the
bacterium. The types of traumatic injuries most commonly
associated with V. vulniﬁcus infection include puncture wounds,
lacerations, scratches, or abrasions sustained while handling
contaminated shellﬁsh, ﬁnﬁsh, knives (or other devices used in
the cleaning or processing of seafood), or ﬁshhooks and those
sustained while stepping on or handling sharp objects or marine
organisms (e.g., crustaceans or possibly stingray spines) in
contaminated water.1,2,4,5,11 The severity of infection may vary
from mild and self-limited to severe. Like gastroenteritis, mild to
moderate wound infection may affect ‘normal’ individuals, i.e.,
those not characteristic of a previously mentioned high-risk
group.1,2,4,5,11 Similar to primary sepsis, symptoms usually occur
within 7 days, although could be delayed as long as 12 days
following exposure.1,4,6,11 More serious infection is characterized
by cutaneous lesions such as bullae, cellulitis, or ecchymosis
surrounding the site of inoculation. Intense pain and swelling are
also present. Skin manifestations may progress to necrotizing
fasciitis, necrotizing vasculitis, or gangrene.1,2,4,5,6,11 In contrast to
primary sepsis, skins lesions are limited to the affected limb or areaof inoculation; metastatic infection is not observed. Bacteremia
and secondary sepsis is common with more severe wound
infection. Systemic effects include fever, hypotension or shock,
chills, and mental status changes.1,2,4,5,6,11 Leukocytosis is com-
mon, however thrombocytopenia and DIC appear to be limited to
the more severe cases.11,72–74 Vomiting and diarrhea are also far
less common than in other forms of V. vulniﬁcus infection
regardless of severity1,2,5,11 (Table 2).
6. Treatment
V. vulniﬁcus is usually susceptible in vitro to multiple
antimicrobial agents. Among the classes of antimicrobial
drugs reliably active against the organism are third-generation
cephalosporins (cefotaxime, ceftriaxone, or ceftazidime), beta-
lactam–beta-lactamase inhibitors (piperacillin–tazobactam), car-
bapenems (imipenem–cilastatin), tetracyclines (minocycline or
doxycycline), aminoglycosides (gentamicin or amikacin), ﬂuor-
oquinolones (ciproﬂoxacin, moxiﬂoxacin, or levoﬂoxacin), and
miscellaneous agents such as trimethoprim–sulfamethoxazole or
chloramphenicol.75–81 The CDC recommends treatment of wound
infections in adults with ceftazidime 1 to 2 g IV/intramuscular (IM)
every 8 h in combination with doxycycline 100 mg IV/peroral (PO)
twice daily (7 to 14 days). The literature consensus for primary
sepsis is similar, with ceftazidime 2 g IV every 8 h in combination
again with doxycycline 100 mg IV/PO every 12 h. Combination
antimicrobial therapy appears to be the preferred regimen for
serious infection, although some animal studies suggest mono-
therapy (e.g., ﬂuoroquinolone) may be just as effective. An
alternative regimen in adults includes cefotaxime 2 g every 8 h
in combination with ciproﬂoxacin 400 mg every 12 h. Ciproﬂoxa-
cin and cefotaxime can also replace doxycycline and ceftazidime,
respectively, in the preferred or consensus regimen. Although rare
in children, the CDC recommends trimethoprim–sulfamethoxazole
and an aminoglycoside for pediatric patients with wound
infections.82
Surgical intervention should be considered absolutely essential
for patients with a severe soft-tissue infection such as necrotizing
fasciitis.83–85 Antimicrobial therapy alone is usually ineffective and
may not achieve therapeutic levels at the site of infection due to
thrombosis of the blood vessels supplying the affected area.
Aggressive surgical debridement is necessary to remove necrotic
tissue and reduce the bacterial burden. Survival with necrotizing
fasciitis has been shown to improve dramatically when adequate
debridement and fasciotomy are performed early.73 Another non-
pharmacologic intervention, hyperbaric oxygen, has been advo-
cated as adjunctive therapy to aggressive antimicrobial therapy.86
One anecdotal report suggested this combined approach may have
eliminated the need for grafting in a patientwith necrotic lesions of
the right hand, arm, and shoulder.80
7. Prevention
The CDC has published recommendations for preventing V.
vulniﬁcus infections. These are especially applicable to individuals
with liver disease or those who are immunocompromised. The
recommendations are listed below and can be found on the CDC
website (http://www.cdc.gov/nczved/divisions/dfbmd/diseases/
vibriov/):
1. Do not eat raw oysters or other raw shellﬁsh.
2. Cook shellﬁsh (oysters, clams, mussels) thoroughly.
3. For shellﬁsh in the shell, either (a) boil until the shells open and
continue boiling for 5moreminutes, or (b) steam until the shells
open and then continue cooking for 9 more minutes. Do not eat
Table 2
Percentage (%) of patients with various signs and symptoms by clinical syndrome and epidemiologic study
Study, year [Ref.]
Blake et al.,
1979 [11]
Tacket et al.,
1984 [5]
Klontz et al.,
1988 [1]b
Paik et al.,
1995 [70]
Shapiro et al.,
1998 [4]
Dechet et al.,
2008 [2]
Gastrointestinal n=7 n=23
Nausea 71
Vomiting 29 68
Diarrhea 100 84
Fever 57 59
Chills 43
Mortality 0 9
Primary septicemia n=24 n=18 n=38 n=92 n=181
Nausea 58 59 58
Vomiting 21 54 42 25 54
Diarrhea 17 58 42 33 58
Abdominal pain/cramps 53 34 26 53
Fever 92 91 92 47 91
Chills 82 53 43
Mental status change 49 50 49
Bullae 37 57
Ecchymosis 32
Cellulitis 50
Fasciitis 18
Myonecrosis 5
Hypotensiona 38 64 32 52 64
Mortality 46 61 55 58 61
Wound infection n=15 n=9 n=17 n=189 n=428
Nausea 38 38
Vomiting 20 50 6 26
Diarrhea 0 13 6 18
Abdominal pain/cramps 0 0 11
Fever 80 88 65 76 72
Chills 46 100 29
Mental status change 18
Bullae 41 48
Ecchymosis 18
Cellulitis 88 91 85
Fasciitis
Myonecrosis 12
Hypotensiona 14 22 12 30 25
Mortality 7 22 24 17 17
a Systolic blood pressure<90mmHg for Klontz et al. (Ref. 1), Shapiro et al. (Ref. 4), and Dechet et al. (Ref. 2);<85mmHg for Tacket et al. (Ref. 5);<80mmHg for Blake et al.
(Ref. 11); not deﬁned for Paik et al. (Ref. 70).
b Includes 12 total patients listed in Tacket et al. data, Ref. 5.
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oysters at least 3 minutes, or fry them in oil at least 10 minutes
at 375 8F.
4. Avoid cross-contamination of cooked seafood and other foods
with raw seafood and juices from raw seafood.
5. Eat shellﬁsh promptly after cooking and refrigerate leftovers.
6. Avoid exposure of open wounds or broken skin to warm salt or
brackish water, or to raw shellﬁsh harvested from such waters.
7. Wear protective clothing (e.g., gloves) when handling raw
shellﬁsh.
8. Wear protective footwear (e.g., wading shoes) when wading in
warm salt or brackish water.87
8. Final comments about the illustrative case
The case presented earlier describes a patient with a necrotizing
soft-tissue infection and sepsis. The patient had shucked and eaten
raw oysters a few days prior to admission. The hands were never
examined closely for lacerations or other skin breaks. Although not
mentioned in the case, the patient was admitted in mid-July when
water temperatures and V. vulniﬁcus colony counts are typically
high.4,8 The oysters were purchased from a vendor along the upper
GulfCoast, however the sourceor locationofharvestwasnotknown.
The patient had chronic liver disease, a well-recognized risk factor
forV. vulniﬁcus infection. The lack of anobviouswound and ahistory
of raw oyster ingestionwould suggest a diagnosis of primary sepsis.However, this casemaybemore of amedical enigma than it appears.
A more complete analysis of potential portals of entry suggests the
site may not be limited to the gastrointestinal tract. It is also quite
possible the organism entered through both hands, or even a
combination of both hands and the gastrointestinal tract. The
uniform and symmetric distribution as well as the ascending
progression of the soft-tissue injury suggests a cutaneous portal of
entry,presumably frombothhands.Variouscontactpointsonoyster
shells are typically razor sharp and easily capable of inﬂicting ﬁne
painless lacerations. The failure to use gloves or some type of
protective device in the shucking process may have resulted in
abrasions or lacerations that were not particularly conspicuous on
admission. Oysters are usually shucked by holding the bivalve in a
protected hand and inserting an oyster knife (or any similar dull,
tapered, thin, and ﬂat device) between the shells adjacent to or
directly into the ‘hinge’. The ‘hinge’ is the ﬁbrous connection
between the valves (shells) and is located at the narrow end of the
oyster.88,89 Cases of spontaneous cellulitis associated with V.
vulniﬁcus have been reported on limbs without an obvious portal
of entry.5,73,83,90–93 This would suggest that visible skin breaks or
wounds are not absolutely necessary for cases of soft-tissue
infection of limbs exposed to contaminated water or seafood.
Therefore, it seems likelyV.vulniﬁcusmaybecapableof invadingand
producing disease through micro-injury of the skin.
Alternatively, the portal of entry could have been the
gastrointestinal tract since, to the best of our knowledge, the
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case of primary sepsis. On admission, the patient was in septic
shock and had obvious skin involvement including bullae. Both
hands were extremely painful. Cutaneous lesions, particularly
bullae, are common and considered blood-borne or metastatic
sequelae of primary sepsis. The usual sites of skin manifestations
are one or both lower extremities and the trunk.5,11,68,94 In
contrast to wound infection, cutaneous lesions associated with
primary septicemia occur less frequently on the arms and
especially the hands. To the best of our knowledge, all case
reports of upper extremity involvement have been characterized
by either diffuse distribution involving bilateral upper and lower
extremities or a single limb.11,95–97 The distribution of metastatic
skin manifestations with the same bilateral symmetry seen in
our patient has not been described in other series. The presumed
sources of the infection, i.e., raw oysters, were probably in close
contact with the affected integument. The blood cultures were
also negative. The patient did not receive any antibiotics prior to
the collection of blood cultures. Although the presence of the
organism in the blood is not an absolute requirement for the
diagnosis of primary septicemia, many reported cases with
cutaneous involvement have been characterized by bacter-
emia.1,5,11 The patient also reported no gastrointestinal symp-
toms prior to admission.
The bacterium could have entered our patient through the
hands and the gastrointestinal tract. It would be very difﬁcult or
even impossible to determine the likelihood of this happening.
This would require the presence of manifestations unique to
primary sepsis as well as those unique to severe wound infection.
Unfortunately, there is considerable overlap with the signs and
symptoms associatedwith both syndromes. Literature analyses of
either primary septicemia or wound infection excluded patients
with more than one potential access point for the organ-
ism.1,4,11,17 As a result, there is very little information describing
the spectrum of illness in patients with more than one possible
portal of entry.
9. Conclusions
V. vulniﬁcus is a motile, halophilic, Gram-negative bacillus
found worldwide, primarily in warm coastal waters. The
bacterium is capable of causing illness ranging from mild
gastroenteritis to necrotizing soft-tissue infection and septic
shock. Severe infection occurs primarily in patients with chronic
liver diseases, immunodeﬁciency, and iron storage diseases.
Despite the large number of individuals at risk for infection, the
reported number of cases of V. vulniﬁcus-related disease is
relatively small. Most infections in the USA occur from April to
October when bacterial counts are higher. Most cases result from
ingestion or handling of raw contaminated seafood (usually raw
oysters in the USA) or from exposure of open wounds to seawater.
The organism possesses several virulence determinants including
resistance to stomach acid, exotoxins, capsular polysaccharide,
siderophores, destruction of macrophages and lymphocytes
through apoptosis, lipopolysaccharide, pili, and ﬂagellum. V.
vulniﬁcus-related infection is usually characterized by three
syndromes: gastroenteritis, primary sepsis, and wound infection.
Primary sepsis is caused by ingestion of raw or uncooked seafood
and has the worst prognosis with a case-fatality rate exceeding
50%. Several classes of antimicrobial agents are active in vitro
againstV. vulniﬁcus. Ceftazidime in combinationwith doxycycline
is the preferred antimicrobial regimen for hospitalized patients.
The CDChas published recommendations for preventing infection
with V. vulniﬁcus. These recommendations are particularly
applicable to high-risk individuals with chronic liver diseases,
immunodeﬁciency, or iron storage diseases.Conﬂict of interest
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